ReviewLife (Basel, Switzerland)2022
Up-Date on Diabetic Nephropathy.
Review in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- Efficacy and potential pharmacological mechanism ofRenal failure · 2025Pooled it
- Correlation of serum irisin levels with diabetic nephropathy: an exhaustive systematic appraisal and meta-analytical investigation.Frontiers in endocrinology · 2025Pooled it
- Review
- Nonmedical Factors That Influence Diabetes Complications and Multilevel Strategies to Reduce Disparities and Improve Outcomes in the U.S.Diabetes care · 2026Article
- The evolving concept from Cardiovascular-kidney-metabolic syndrome to metabolic associated liver-cardiovascular-kidney syndrome: insights from endocrinology.Reviews in endocrine & metabolic disorders · 2026Review
- The Role and Clinical Significance of miR-484 in the Regulation of SGLT2 in Diabetic Nephropathy.International journal of endocrinology · 2026Article
- Translational advances in diabetic nephropathy management: integrating nanoformulation-based drug delivery systems.Frontiers in medical technology · 2026Review
- Prevalence of anemia in patients with chronic kidney disease attended at a nephrology outpatient clinic and its association with the outcome of renal replacement therapy over five years: a retrospective cohort study, Municipality of São Paulo, 2010-2018.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2026Article
- Identifying Diabetic Kidney Disease in Type 2 Diabetes Patients Using Explainable Machine Learning: A Case-Control Study.Journal of diabetes research · 2026Article
- A PRECEDE-PROCEED-based educational program: enhancing self-care and quality of life with implications for biochemical outcomes in hemodialysis patients.Frontiers in public health · 2026Article
- Dysregulation of miR-21-5p in diabetic nephropathy and its role in inflammatory response.Journal of diabetes investigation · 2025Article
- Multi-Target Modulation of Polyphenols in Diabetic Kidney Disease Therapeutics: A Comprehensive Review.Food science & nutrition · 2025Review
- Article
- Overexpression of PON1 reduces high glucose induced renal tubular epithelial cell injury by activating PPARγ signaling pathway to alleviate diabetes nephropathy.Archives of endocrinology and metabolism · 2025Article
- Network Pharmacology, Molecular Dynamics Simulation, and Biological Validation Insights into the Potential of Ligustri Lucidi Fructus for Diabetic Nephropathy.International journal of molecular sciences · 2025Article
- Decoding diabetic kidney disease: a comprehensive review of interconnected pathways, molecular mediators, and therapeutic insights.Diabetology & metabolic syndrome · 2025Review
- Construction of a metabolic-immune model for predicting the risk of diabetic nephropathy and study of gut microbiota.Journal of diabetes investigation · 2025Article
- Study on effect of pancreatic kininogenase on diabetic nephropathy-induced fibrosis via Notch1/Hes1/Pten/Akt signaling pathway.BMC nephrology · 2025Article
- The Role of Resistin in Macrovascular and Microvascular Complications of Type 2 Diabetes.Life (Basel, Switzerland) · 2025Review
- A SuperLearner approach for predicting diabetic kidney disease upon the initial diagnosis of T2DM in hospital.BMC medical informatics and decision making · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is one of the leading causes of kidney disease. Diabetic kidney disease (DKD) is a major cause of end-stage kidney disease (ESKD) worldwide, and it is linked to an increase in cardiovascular (CV) risk. Diabetic nephropathy (DN) increases morbidity and mortality among people living with diabetes. Risk factors for DN are chronic hyperglycemia and high blood pressure; the renin-angiotensin-aldosterone system blockade improves glomerular function and CV risk in these patients. Recently, new antidiabetic drugs, including sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 agonists, have demonstrated additional contribution in delaying the progression of kidney disease and enhancing CV outcomes. The therapeutic goal is regression of albuminuria, but an atypical form of non-proteinuric diabetic nephropathy (NP-DN) is also described. In this review, we provide a state-of-the-art evaluation of current treatment strategies and promising emerging treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.